Nordic Nanovector Announces that the data from the LYMRIT 37-05 Phase 1 Trial of Betalutin® in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) will be presented at EHA 2022 Meeting
Oslo, Norway, 10 June 2022 Nordic Nanovector ASA (OSE: NANOV) announces an update from the LYMRIT 37-05 Phase 1 trial investigating Betalutin® ([177]Lu lilotomab satetraxetan) in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) not eligible for stem cell transplantation. The latest data to be presented at the European Hematology Association (EHA) Congress in Vienna, Austria on 10 June 2022 shows that Betalutin® continues to be well tolerated with no further dose-limiting toxicity (DLT). The data analysis showed that clinical activity of Betalutin® was seen